reversed-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-08-01 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Peptide-based pharmaceutical products such as tirzepatide require controlled temperature management to preserve structural integrity. Manufacturer labeling generally specifies refrigeration at 2 to 8 degrees Celsius before first use, with protection from light and freezing. Exposure to repeated temperature cycling can promote aggregation or deamidation, which alters the analytical profile even when the visible solution appears unchanged. Once a product is in use, the permitted storage window and temperature range are defined by the specific labeled presentation rather than by general peptide rules.
Robinson and another colleague, Pauling founded the Institute of Orthomolecular Medicine in Menlo Park, California, which was soon renamed the Linus Pauling Institute of Science and Medicine. Pauling directed research on vitamin C, but also continued his theoretical work in chemistry and physics until his death. In his last years, he became especially interested in the possible role of vitamin C in preventing atherosclerosis and published three case reports on the use of lysine and vitamin C to relieve angina pectoris. During the 1990s, Pauling put forward a comprehensive plan for the treatment of heart disease using lysine and vitamin C. In 1996, a website was created expounding Pauling's treatment which it referred to as Pauling Therapy. Proponents of Pauling Therapy believe that heart disease can be treated and even cured using only lysine and Vitamin C and without drugs or heart operations. Pauling's work on vitamin C in his later years generated much controversy. He was first introduced to the concept of high-dose vitamin C by biochemist Irwin Stone in 1966. After becoming convinced of its worth, Pauling took 3 grams of vitamin C every day to prevent colds. Excited by his own perceived results, he researched the clinical literature and published Vitamin C and the Common Cold in 1970. He began a long clinical collaboration with the British cancer surgeon Ewan Cameron in 1971 on the use of intravenous and oral vitamin C as cancer therapy for terminal patients.
Reception to the advertisement was mixed, as some social media users thought its mention of genetics evoked eugenicist ideas. The Dunkin' campaign launched less than a week after American Eagle launched its campaign "Sydney Sweeney Has Great Jeans", which led to similar backlash. On February 8, 2026, during Super Bowl LX, Ben Affleck appeared in a commercial that parodies Good Will Hunting, a film that Affleck co-wrote and starred in, as a 1990s sitcom. He portrays "Will Dunkin'" a parody of Damon's character, "Will Hunting", where he's cast alongside 1990s sitcom stars such as Jason Alexander, Jennifer Aniston, Jasmine Guy, Alfonso Ribeiro, Matt LeBlanc, and Jaleel White. Tom Brady also appears in the commercial.
The Supreme Soviet (successor of the Congress of Soviets) was nominally the highest organ of state authority for most of the Soviet history, at first acting as a rubber stamp institution, approving and implementing all decisions made by the party. However, its powers and functions were extended in the late 1950s, 1960s, and 1970s, including the creation of new state commissions and committees. It gained additional powers relating to the approval of the Five-Year Plans and the government budget. The Supreme Soviet elected a Presidium (successor of the Central Executive Committee) to wield its power between plenary sessions, ordinarily held twice a year, and appointed the Supreme Court, the Procurator General and the Council of Ministers (known before 1946 as the Council of People's Commissars), headed by the Chairman (Premier) and managing an enormous bureaucracy responsible for the administration of the economy and society. State and party structures of the constituent republics largely emulated the structure of the central institutions, although the Russian SFSR, unlike the other constituent republics, for most of its history had no republican branch of the CPSU, being ruled directly by the union-wide party until 1990. Local authorities were organized likewise into party committees, local Soviets and executive committees. While the state was a de jure federation with a nominally federal constitution, the party was de facto centralized and unitary. The state security police (the KGB and its predecessor agencies) played an important role in Soviet politics.
=== Early work === After completing her medical training in 1912, Lawrence briefly worked as a resident pathologist in Boston. That same year, she relocated to Portland, Oregon where she worked with tuberculosis specialist Ralph Matson. Lawrence established her own clinical laboratory in the Selling Building in 1913. She directed the laboratory for more than fifty years, providing diagnostic services to physicians and public agencies throughout Oregon. Lawrence conducted experimental work related to infectious disease and kept laboratory animals, including guinea pigs, at her home on Southeast Peacock Lane for research purposes.
Sources: en.wikipedia.org
Prepared commercial blends may be sold as a powder or as a concentrated gelatinous block, divided into small squares. Either type is mixed with sufficient hot water to completely dissolve it, and then mixed with enough cold water to make the volume of liquid specified on the packet. The solubility of powdered gelatine can be enhanced by sprinkling it into the liquid several minutes before heating, "blooming" the individual granules. The fully dissolved mixture is then refrigerated, slowly forming a colloidal gel as it cools. Gelatine desserts may be enhanced in many ways, such as using decorative moulds, creating multicoloured layers by adding a new layer of slightly cooled liquid over the previously solidified one, or suspending non-soluble edible elements such as marshmallows or fruit. Some types of fresh fruit and their unprocessed juices are incompatible with gelatine desserts; see the Chemistry section below. When fully chilled, the most common ratios of gelatine to liquid (as instructed on commercial packaging) usually result in a custard-like texture which can retain detailed shapes when cold but melts back to a viscous liquid when warm. A recipe calling for the addition of additional gelatine to regular jelly gives a rubbery product that can be cut into shapes with cookie cutters and eaten with fingers (called "Knox Blox" by the Knox company, makers of unflavoured gelatine). Higher gelatine ratios can be used to increase the stability of the gel, culminating in gummy candies which remain rubbery solids at room temperature (see Bloom (test)).
== Adverse effects == Side effects observed in fluoxetine-treated persons in clinical trials with an incidence >5% and at least twice as common in fluoxetine-treated persons compared to those who received a placebo pill include abnormal dreams, abnormal ejaculation, anorexia, anxiety, asthenia, diarrhea, dizziness, dry mouth, dyspepsia, fatigue, flu syndrome, impotence, insomnia, decreased libido, nausea, nervousness, pharyngitis, rash, sinusitis, somnolence, sweating, tremor, vasodilation, and yawning. Fluoxetine is considered the most stimulating of the SSRIs (that is, it is most prone to causing insomnia and agitation). It also appears to be the most prone of the SSRIs for producing dermatologic reactions (e.g. urticaria (hives), rash, itchiness, etc.).
After receiving a missile targeting device disguised as a gem from Agent Abrella, she travels to Earth in the Kaijuki Devil Capture 5 (デビルキャプチャー5, Debiru Kyapuchā Faibu), which is destroyed by Deka Bike Robo while she is captured by S.P.D.'s Earth unit. She escapes to rekindle a former relationship, but is confronted by the Dekarangers and learns of Abrella's true intentions. Once the Dekarangers stop the missile and jettison Faraway to safety, she is pardoned. Faraway is portrayed by Aja (あじゃ). Tokasaian Princess Io Yonmerluicchi (トカーサ星人イオ・ヨンマールイッチ, Tokāsa Seijin Io Yonmāruitchi): A princess from Planet Tokasa who resembles Umeko. Io Yonmerluicchi is portrayed by Mika Kikuchi, who also portrays Umeko. Chanbenarian Gin (チャンベーナ星人ギン, Chanbēna Seijin Gin): A feline alien child from Planet Chanbenar who tries to steal medicine from Hakutaku, for his sick mother, after he was unable to buy it with a pearl he found, but is stopped and befriended by Sen-chan. After surviving an attempt on his life by an Alienizer named Gineka, who used the pearl in his Kaijuki game, Gin's mother receives medicine from Hakutaku at Sen-chan's request. Gin is voiced by Yōko Teppōzuka (鉄炮塚 葉子, Teppōzuka Yōko). Teranian Chou San (テラン星人チョウ・サン, Teran Seijin Chō San): A retired veteran detective from Planet Teran who seeks revenge on an Alienizer named Raja Namunan for killing his daughter 13 years prior, but was never able to prove it. In the present, Jasmine shows him the errors of his ways while confirming his theory. Chou San is voiced by Seizō Katō (加藤 精三, Katō Seizō).
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.